Chronic Hepatitis D

Infectious Diseases
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Mirum Pharmaceuticals
Mirum PharmaceuticalsFOSTER CITY, CA
1 program
1
BrelovitugPhase 2/31 trial
Active Trials
NCT07454837Recruiting120Est. Mar 2029
GS
Gilead SciencesFOSTER CITY, CA
2 programs
Burden of Hepatitis D Virus (HDV) Infection in ItalyN/A1 trial
Burden of Hepatitis D Virus (HDV) Infection in ItalyN/A
Active Trials
NCT05723068Completed515Est. Dec 2024

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
2028
2029
Mirum PharmaceuticalsBrelovitug
Gilead SciencesBurden of Hepatitis D Virus (HDV) Infection in Italy

Clinical Trials (2)

Total enrollment: 635 patients across 2 trials

Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide

Start: Feb 2026Est. completion: Mar 2029120 patients
Phase 2/3Recruiting
NCT05723068Gilead SciencesBurden of Hepatitis D Virus (HDV) Infection in Italy

Burden of Hepatitis D Virus (HDV) Infection in Italy

Start: Aug 2022Est. completion: Dec 2024515 patients
N/ACompleted

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 635 patients
2 companies competing in this space